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-a risk factor for nevirapine or efavirenz resistance. 4 In another similar randomized study with higher adherence levels, 5 6 out of 39 patients who discontinued the study early had virological failure with resistance with efavirenz, didanosine and lamivudine once daily versus only 1 out of 54 with efavirenz, lamivudine and zidovudine twice daily (P¼0.02, by Fisher's exact test). It is noteworthy that noninferiority of the once-daily regimen was demonstrated in the end.
The rationalized choice for antiretroviral therapy in clinical practice is usually based on randomized studies conducted among selected subjects with better adherence. Rey et al. 1 should be commended for waiving this principle, but their conclusion only applies to the population studied. In my opinion, larger studies with higher adherence are needed to assess the intrinsic efficacy of nevirapine, tenofovir and lamivudine (or emtricitabine) once daily. On the other hand, their report elegantly suggests that the intuitive 'simpler is better' for starting antiretroviral therapy among individuals with adherence problems may not always be true.
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J.-J. P. has received prior grant support from Abbott and Boehringer-Ingelheim. that simpler is not always better, even if the adherence rate was better with once-daily regimens than with twice-daily regimens according to a recent meta-analysis 3 (but the effect was only modest and more pronounced at the time of treatment initiation). Treatment interruptions are a risk factor for non-nucleotide reverse transcriptase inhibitor (NNRTI) resistance development, but no difference has been shown when nevirapine was administered once or twice a day. 4 More early virological failures with resistance to efavirenz have been observed with didanosine/lamivudine/efavirenz once a day compared with zidovudine/lamivudine þ efavirenz twice a day, 5 but the adherence rate was not different between treatment arms; therefore, the resistance mutations are probably more associated with the NRTI background choice.
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Despite a non-optimal adherence rate with the once-daily regimen in the DAUFIN trial, the high virological failure rate remains unexplained, and the same virological failures have been observed in a study by Lapadula et al., 6 which evaluated the tenofovir, emtricitabine and nevirapine combination, but with a twice-a-day nevirapine administration.
Finally, if we agree that simpler is not always better, on the other hand, it is not worse. According to clinical trials, as well as real life, most of the patients on antiretroviral treatment remain in virological success while more and more combinations are administered once daily.
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*Corresponding author. Tel: þ359-2-9821451; Fax: þ359-2-9542875; E-mail: emma_keuleyan@yahoo.com Sir, We read with great interest the recently published review 'Aminoglycoside drugs in clinical practice: an evidence-based approach'. 1 We welcome the authors' intention to present an evidence-based approach to aminoglycoside use, which they do in the form of a systematic review of the literature, followed by a meta-analysis.
We would like to raise several points:
(i) The authors have stated that 'Resistant bacteria have renewed our interest in the aminoglycoside drugs'. While this is partly true, we would argue that interest has never diminished as these drugs are widely used, regarded as being effective as monotherapy and in combination, and are being increasingly seen as a treatment and surgical prophylactic alternative to many b-lactam antibiotics, which, rightly or wrongly, are perceived as more potent initiators of Clostridium difficile colitis. (ii) The authors state that there is interest in aminoglycoside use for Gram-negative infections that are resistant to 'more efficacious and less toxic drugs'. We would question which drugs are more efficacious and of course if the organisms are resistant to these agents, efficacy would be unlikely. (iii) Later, the reader's attention is drawn to Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella spp. (because they are resistant to the above-mentioned drugs), with the statement that 'The alternatives are usually aminoglycosides, colistin and ( potentially) tigecycline', with a suggestion for comparative clinical trials. As far as we know, Acinetobacter spp. are inherently resistant to aminoglycosides.
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(iv) Regarding infective endocarditis, the authors recommend that 'Practitioners would be well advised to use published guidelines, but within their limits, to take into account the fact that combination treatment is not supported by evidence'. The authors point out that trials with small numbers of patients were in favour of monotherapy (without aminoglycosides), but they 'did not reach statistical significance'. Lack of evidence is not an argument against a practice. Such recommendations made by the working groups of scientific
